atai And Beckley Merger Advances Strategic Vision For Psychedelic Drug Development With Deep CNS Expertise

Benzinga · 06/02 10:15
  • Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic
  • Combined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizations
  • Topline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S.
  • The all-share transaction is expected to close in the second half of 2025
  • Concurrent $30.0M private placement by Ferring Ventures S.A. and Adage Capital Partners LP